WB, IP, IHC-P, IF-IC
H M Mk
Endogenous
123
Rabbit IgG
#O14980
7514
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
| Immunohistochemistry (Paraffin) | 1:300 - 1:1200 |
| Immunofluorescence (Immunocytochemistry) | 1:400 - 1:1600 |
Storage
For a carrier free (BSA and azide free) version of this product see product #49000.
Specificity / Sensitivity
Species Reactivity:
Human, Mouse, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the carboxy terminus of human exportin-1/CRM1 protein.
Background
Exportins are a family of seven proteins that are responsible for intracellular transport. Exportin-1, also known as chromosome region maintenance 1 (CRM1), is a protein essential for nuclear export of hundreds of proteins, mRNAs, and rRNAs (1-3). Exportin-1 binds to substrates with nuclear export signals (NESs) rich in leucine and other hydrophobic amino acids (4). These hydrophobic sequences form an alpha-helix-loop that can bind to the exportin-1 hydrophobic groove (5). Studies have shown that these NESs can be modified either by protein modifications or by mutation to regulate exportin-1 binding (6-7). Targets of exportin-1 include many tumor suppressors, such as Rb, p53, FoxO1, BAF47, as well as oncoproteins, such as p21 and p27 (1). In addition, Myc can upregulate exportin-1 during biogenesis, where it can export newly formed 40S and 60S subunits from the nucleoli (8-9).
Inhibition of nuclear export has been pursued for therapeutic application since the finding that leptomycin B could suppress HIV replication by suppressing the ability of exportin-1 to export the HIV-1 protein Rev (2, 10). Overexpression of exportin-1 has been associated with poor prognosis in various cancer types (11-13). Genomic approaches and development of inhibitors have identified exportin-1 as a druggable target (14-16). The use of various inhibitors of exportin-1 is also being explored in various antiviral therapies (17-18).
- Xu, D. et al. (2012) Mol Biol Cell 23, 3673-6.
- Ossareh-Nazari, B. et al. (1997) Science 278, 141-4.
- Fukuda, M. et al. (1997) Nature 390, 308-11.
- Kutay, U. and Güttinger, S. (2005) Trends Cell Biol 15, 121-4.
- Dong, X. et al. (2009) Nat Struct Mol Biol 16, 558-60.
- Vogt, P.K. et al. (2005) Cell Cycle 4, 908-13.
- Craig, E. et al. (2002) EMBO J 21, 31-42.
- Thomas, F. and Kutay, U. (2003) J Cell Sci 116, 2409-19.
- Golomb, L. et al. (2012) Mol Cell 45, 222-32.
- Wolff, B. et al. (1997) Chem Biol 4, 139-47.
- Noske, A. et al. (2008) Cancer 112, 1733-43.
- Shen, A. et al. (2009) Neurosurgery 65, 153-9; discussion 159-60.
- Yao, Y. et al. (2009) Oncol Rep 21, 229-35.
- Schmidt, J. et al. (2013) Leukemia 27, 2357-65.
- Boyle, S.M. et al. (1999) J Virol 73, 6872-81.
- Walker, C.J. et al. (2013) Blood 122, 3034-44.
- Yadav, V. et al. (2016) Virusdisease 27, 357-368.
- Chutiwitoonchai, N. et al. (2017) Virology 507, 32-39.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation IHC-P: Immunohistochemistry (Paraffin) IF-IC: Immunofluorescence (Immunocytochemistry)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
